Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992161 | 0.98 | BACE1 (0.39) | BACE1CES2CES1MAPK1NPSR1 | |
| SCHEMBL1403176 | 0.96 | BACE1 (0.40) | BACE1MAPTSMN1; SMN2GAA | |
| SCHEMBL7993286 | 0.92 | BACE1 (0.41) | BACE1NPSR1MAPTSMN1; SMN2GAA | |
| SCHEMBL695478 | 0.86 | BACE1 (0.38) | BACE1 | |
| SCHEMBL16701732 | 0.84 | GABRA1 (0.38) | BACE1 | |
| SCHEMBL16197279 | 0.80 | MAPT (0.37) | BACE1ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL16701535 | 0.79 | BACE1 (0.37) | BACE1ALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL1018668 | 0.79 | BACE1 (0.41) | BACE1 | |
| SCHEMBL1014697 | 0.77 | BACE1 (0.38) | BACE1 | |
| SCHEMBL1768845 | 0.76 | BACE1 (0.36) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| EP-2292228-A1 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | AstraZeneca AB (Publ) (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
| US-5859283-A | TERTIARY-BUTYL 3-CYCLOALKYL-3-OXOPROPIONATE | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1999-01-12 | — | — | US | disclosed |
| US-5747424-A | HEATING AN AROMATIC DIKETONE WITH A SALT OF HYDROXYLAMINE IN A SOLVENT | RHONE-POULENC AGRICULTURE LTD. (GB) | 1998-05-05 | — | — | US | disclosed |
| US-5656573-A | Herbicidal 4-substituted isoxazoles | RHONE-POULENC AGRICULTURE LTD. (GB) | 1997-08-12 | — | — | US | disclosed |
| US-5650533-A | Intermediates to herbicidal 4-substituted isoxazoles | RHONE-POULENC AGRICULTURE LTD. (GB) | 1997-07-22 | — | — | US | disclosed |
| EP-0418175-B1 | Isoxazoles herbicides | RHONE POULENC AGRICULTURE (GB) | 1996-07-17 | — | — | EP | disclosed |
| EP-0418175-A2 | Isoxazoles herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | BACE1 280/4885CES2 1318/4885CES1 82/4885 |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | BACE1 280/4885CES2 1318/4885CES1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.